Oncology
🇺🇸 FDA Page 7FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 73–84 of 246 articles
MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug
Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial
FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
ANVISA Clinical Trial Changes Brazil: What You Need to Know
African Medicines Agency impact: Harmonizing Clinical Trials in Africa
FDA Accelerated Approval Pathway: Impact on Oncology Market Access & Pricing in 2026
FDA Guidance on Oncology Drugs: New Rules for Accelerated Approval
COFEPRIS Approval Pathway: Insights on Novel Immunotherapies for Advanced Melanoma